Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
13.68
+0.44 (3.32%)
Jun 29, 2026, 3:00 PM CST
SHA:600535 Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, SHA:600535 stock has a consensus rating of "Buy" and an average price target of ¥17.18. The average 1-year stock price forecast is 25.58% higher than the current stock price, while the lowest is ¥14.00 (+2.34%) and the highest is ¥18.70 (+36.70%).
Price Target: ¥17.18 (+25.58%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SHA:600535 stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 5 | 5 | 5 |
Financial Forecast
Revenue This Year
9.00B
from 8.24B
Increased by 9.21%
Revenue Next Year
9.87B
from 9.00B
Increased by 9.72%
EPS This Year
n/a
EPS Next Year
n/a
Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 9.1B | ||
| Avg | 9.0B | ||
| Low | 8.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 10.7% | ||
| Avg | 9.2% | ||
| Low | 5.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |